Lynn Anne Bristol

Array ( [id] => 16770919 [patent_doc_number] => 10982008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Domain-exchanged antibody [patent_app_type] => utility [patent_app_number] => 15/521891 [patent_app_country] => US [patent_app_date] => 2015-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 31 [patent_no_of_words] => 26675 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 503 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806554 [patent_doc_number] => 20160152712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER RESISTANT TO A TYROSINE KINASE INHIBITOR (TKI)' [patent_app_type] => utility [patent_app_number] => 14/956585 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 35572 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14956585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786307 [patent_doc_number] => 20180153938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => NK Cells and Antibodies for Cancer Treatment [patent_app_type] => utility [patent_app_number] => 15/571593 [patent_app_country] => US [patent_app_date] => 2015-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10797871 [patent_doc_number] => 20160144028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/949303 [patent_app_country] => US [patent_app_date] => 2015-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 24954 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14949303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813754 [patent_doc_number] => 20160159913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/947865 [patent_app_country] => US [patent_app_date] => 2015-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 53018 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14947865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471260 [patent_doc_number] => 20170058043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/120033 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 9992 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806539 [patent_doc_number] => 20160152698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'ANTI-NGF ANTIBODIES AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/940710 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 58742 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386453 [patent_doc_number] => 20180244768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => HUMAN ANTI-THYROGLOBULIN T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 15/524869 [patent_app_country] => US [patent_app_date] => 2015-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12009724 [patent_doc_number] => 09803029 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-31 [patent_title] => 'Bispecific CD33 and CD3 binding proteins' [patent_app_type] => utility [patent_app_number] => 14/937494 [patent_app_country] => US [patent_app_date] => 2015-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 45 [patent_no_of_words] => 22390 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14937494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10782951 [patent_doc_number] => 20160129108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'THERAPEUTIC COMBINATIONS COMPRISING ANTI-CD73 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/937565 [patent_app_country] => US [patent_app_date] => 2015-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 43295 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14937565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185466 [patent_doc_number] => 20180044399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'INHIBITORY CHIMERIC ANTIGEN RECEPTORS' [patent_app_type] => utility [patent_app_number] => 15/525906 [patent_app_country] => US [patent_app_date] => 2015-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 38446 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15525906 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10737616 [patent_doc_number] => 20160083765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-24 [patent_title] => 'METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES' [patent_app_type] => utility [patent_app_number] => 14/931354 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 38864 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001861 [patent_doc_number] => 20170306016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'Anti-TIM-3 Antibodies' [patent_app_type] => utility [patent_app_number] => 15/521514 [patent_app_country] => US [patent_app_date] => 2015-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 17263 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10760682 [patent_doc_number] => 20160106836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'Immunotherapy Using a Logical AND Combination for Immune Response Activation' [patent_app_type] => utility [patent_app_number] => 14/882862 [patent_app_country] => US [patent_app_date] => 2015-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 6217 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14882862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693800 [patent_doc_number] => 20160039946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'Modified Antibody' [patent_app_type] => utility [patent_app_number] => 14/872290 [patent_app_country] => US [patent_app_date] => 2015-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 10782 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14872290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294447 [patent_doc_number] => 10287340 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Anti-HIV domain antibodies and method of making and using same [patent_app_type] => utility [patent_app_number] => 14/867793 [patent_app_country] => US [patent_app_date] => 2015-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 34 [patent_no_of_words] => 38564 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14867793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17286299 [patent_doc_number] => 11202837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Biological materials and uses thereof [patent_app_type] => utility [patent_app_number] => 15/513393 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 166 [patent_figures_cnt] => 138 [patent_no_of_words] => 63156 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943300 [patent_doc_number] => 20170247452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/514334 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 33160 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806578 [patent_doc_number] => 20160152735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'COMPOSITIONS AND METHODS FOR BINDING LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 14/862117 [patent_app_country] => US [patent_app_date] => 2015-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 65301 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14862117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13278471 [patent_doc_number] => 10150807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => Method for isolation of soluble polypeptides [patent_app_type] => utility [patent_app_number] => 14/851641 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 11663 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14851641 [rel_patent_id] =>[rel_patent_doc_number] =>)